Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Luminex Corporation stock | $23.57

Own Luminex Corporation stock in just a few minutes.

Fact checked

Luminex Corporation is a medical instruments & supplies business based in the US. Luminex Corporation shares (LMNX) are listed on the NASDAQ and all prices are listed in US Dollars. Luminex Corporation employs 1,257 staff and has a trailing 12-month revenue of around USD$396.5 million.

How to buy shares in Luminex Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Luminex Corporation. Find the stock by name or ticker symbol: LMNX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Luminex Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$23.57, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Luminex Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Luminex Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Luminex Corporation share price

Use our graph to track the performance of LMNX stocks over time.

Luminex Corporation shares at a glance

Information last updated 2020-12-02.
Latest market closeUSD$23.57
52-week rangeUSD$20.0697 - USD$41.5379
50-day moving average USD$22.3074
200-day moving average USD$28.1877
Wall St. target priceUSD$37.5
PE ratio 61.005
Dividend yield USD$0.36 (1.52%)
Earnings per share (TTM) USD$0.398

Buy Luminex Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Luminex Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Luminex Corporation price performance over time

Historical closes compared with the close of $23.57 from 2020-12-09

1 week (2021-01-11) -7.89%
1 month (2020-12-18) -3.12%
3 months (2020-10-16) 7.53%
6 months (2020-07-17) -35.03%
1 year (2020-01-17) 1.68%
2 years (2019-01-18) -11.46%
3 years (2018-01-18) 14.20%
5 years (2016-01-15) 21.31%

Is Luminex Corporation under- or over-valued?

Valuing Luminex Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Luminex Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Luminex Corporation's P/E ratio

Luminex Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, Luminex Corporation shares trade at around 61x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Luminex Corporation's PEG ratio

Luminex Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Luminex Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Luminex Corporation's EBITDA

Luminex Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$66.2 million.

The EBITDA is a measure of a Luminex Corporation's overall financial performance and is widely used to measure a its profitability.

Luminex Corporation financials

Revenue TTM USD$396.5 million
Operating margin TTM 9.09%
Gross profit TTM USD$183.8 million
Return on assets TTM 3.34%
Return on equity TTM 3.75%
Profit margin 4.62%
Book value $11.313
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Luminex Corporation shares

There are currently 4.0 million Luminex Corporation shares held short by investors – that's known as Luminex Corporation's "short interest". This figure is 4.9% down from 4.2 million last month.

There are a few different ways that this level of interest in shorting Luminex Corporation shares can be evaluated.

Luminex Corporation's "short interest ratio" (SIR)

Luminex Corporation's "short interest ratio" (SIR) is the quantity of Luminex Corporation shares currently shorted divided by the average quantity of Luminex Corporation shares traded daily (recently around 553171.92254495). Luminex Corporation's SIR currently stands at 7.23. In other words for every 100,000 Luminex Corporation shares traded daily on the market, roughly 7230 shares are currently held short.

However Luminex Corporation's short interest can also be evaluated against the total number of Luminex Corporation shares, or, against the total number of tradable Luminex Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Luminex Corporation's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Luminex Corporation shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Luminex Corporation shares, roughly 111 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Luminex Corporation.

Find out more about how you can short Luminex Corporation stock.

Luminex Corporation share dividends


Dividend payout ratio: 90% of net profits

Recently Luminex Corporation has paid out, on average, around 90% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.52% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Luminex Corporation shareholders could enjoy a 1.52% return on their shares, in the form of dividend payments. In Luminex Corporation's case, that would currently equate to about $0.36 per share.

Luminex Corporation's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Luminex Corporation's most recent dividend payout was on 15 October 2020. The latest dividend was paid out to all shareholders who bought their shares by 23 September 2020 (the "ex-dividend date").

Luminex Corporation share price volatility

Over the last 12 months, Luminex Corporation's shares have ranged in value from as little as $20.0697 up to $41.5379. A popular way to gauge a stock's volatility is its "beta".

LMNX.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Luminex Corporation's is 0.6206. This would suggest that Luminex Corporation's shares are less volatile than average (for this exchange).

Luminex Corporation overview

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site